Is your drug development stuck in these dilemmas?

​Disconnection between R&D and production: Technology transfer takes a long time, with an average delay of 5.8 months (2024 industry report)

CMC changes out of control: Process changes in the clinical stage lead to cost overruns of $2.3 million+

​Supply chain bottleneck: The delay rate of key excipient delivery is as high as 42%, affecting the progress of IND application

Global application is blocked: Duplicate preparation of dual application materials in China and the United States increases the time consumption by 60%

End-to-end service overview: seamless connection from molecule to market

Early discovery: AI-Driven LeadOpt™, lead compound screening cycle shortened by 67%.

Preclinical development: 3D Organ-Chip toxicity prediction model, animal experiments reduced by 80%, with an accuracy rate of 92%.

Clinical production: FlexFactory™ modular production line, batch switching time <6 hours, supporting Phase I-III parallel production.

Commercial supply: Continuous Manufacturing Hub, production cost reduced by 22%, and production capacity elasticity expanded by 300%.

Why did 4 of the world's top 10 pharmaceutical companies choose us?

1. Complex formulation technology matrix

Liposome platform: drug loading efficiency ≥ 95% (industry average 82%), particle size control CV < 5%

Long-acting injection: achieve 6-month sustained release, in vitro and in vivo correlation (IVIVC) r²> 0.98

ADC proprietary technology: DAR4 ratio ≥ 90%, fixed-site coupling patent (patent number: CN2024XXXXXX)

2. Data-driven development system

AI+QbD process optimization: NDA first-pass rate 91.5% (industry average 71%)

Real-time release testing (RTRT): reduce quality control time by 30%

3. Global compliance network

Three-place certification: China NMPA, US FDA, EU EMA GMP simultaneous audit

Seamless declaration: declaration materials are mutually recognized in China, the United States and Europe, saving 1200+ working hours